Journal of Clinical Oncology, Vol 19, Issue 16
(August), 2001: 3692-3705
© 2001 American Society for Clinical Oncology
Prognostic Significance of Pathologic Features in Localized Prostate Cancer Treated With Radical Prostatectomy: Implications for Staging Systems and Predictive Models
By David I. Quinn,
Susan M. Henshall,
Anne-Maree Haynes,
Phillip C. Brenner,
Raji Kooner,
David Golovsky,
Jayne Mathews,
Gordon F. ONeill,
Jennifer J. Turner,
Warick Delprado,
John F. Finlayson,
Robert L. Sutherland,
John J. Grygiel,
Phillip D. Stricker
From the Cancer Research Program, Garvan Institute of Medical Research and Departments of Urology, Anatomical Pathology, and Medical Oncology, St Vincents Hospital, Darlinghurst; and Douglass Hanly Moir Pathology and Sydney Diagnostic Services, North Ryde, Australia.
Address correspondence to Phillip D. Stricker, MD, Department of Urology, St Vincents Clinic, Victoria St, Darlinghurst, New South Wales 2010, Australia; email: stricker{at}ozemail.com.au
PURPOSE: Although predicting outcome for men with clinically localized prostate cancer (PC) has improved, the staging system and nomograms used to do this are based on results from the North American health system. To be internationally applicable, these models require testing in cohorts from a variety of different health systems based on the predominant PC case identification methods used.
PATIENTS AND METHODS: We studied 732 men with localized PC treated with radical prostatectomy and no preoperative therapy between 1986 and 1999 at one Australian institution to determine the effect of clinicopathologic features on disease-free survival.
RESULTS: Preoperative serum prostate-specific antigen (PSA) concentration, Gleason score, pathologic stage, and year of surgery were independent predictors of outcome. Although margin status demonstrated only a trend toward significance in multivariate modeling overall, it proved to be independent in subgroups based on later year of surgery (1986 to 1994 v 1995 to 1998), preoperative PSA of less than 10 ng/mL, and Gleason score 7. Adjuvant radiation therapy improved disease-free survival rates in patients with multiple surgical margin involvement.
CONCLUSION: This work confirms the prognostic significance of pathologic stage, Gleason score, and preoperative serum PSA. In the context of a contemporaneous screening effect in Australia, these findings may have implications for methods that predict outcome following surgery as screening becomes more prevalent in a population. The independent prognostic effect of margin status may alter with an increase in the proportion of screening-identified PCs. Staging systems and nomograms that predict outcome following surgery require validation in cohorts with different health practices before being universally applied.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. M. Henshall, L. G. Horvath, D. I. Quinn, S. A. Eggleton, J. J. Grygiel, P. D. Stricker, A. V. Biankin, J. G. Kench, and R. L. Sutherland
Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
J Natl Cancer Inst,
October 4, 2006;
98(19):
1420 - 1424.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. K. Rasiah, J. G. Kench, M. Gardiner-Garden, A. V. Biankin, D. Golovsky, P. C. Brenner, R. Kooner, G. F. O'Neill, J. J. Turner, W. Delprado, et al.
Aberrant neuropeptide y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis.
Cancer Epidemiol. Biomarkers Prev.,
April 1, 2006;
15(4):
711 - 716.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Xia, S. R. Kumar, R. Masood, S. Zhu, R. Reddy, V. Krasnoperov, D. I. Quinn, S. M. Henshall, R. L. Sutherland, J. K. Pinski, et al.
EphB4 Expression and Biological Significance in Prostate Cancer
Cancer Res.,
June 1, 2005;
65(11):
4623 - 4632.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. R. Bauskin, D. A. Brown, S. Junankar, K. K. Rasiah, S. Eggleton, M. Hunter, T. Liu, D. Smith, T. Kuffner, G. J. Pankhurst, et al.
The Propeptide Mediates Formation of Stromal Stores of PROMIC-1: Role in Determining Prostate Cancer Outcome
Cancer Res.,
March 15, 2005;
65(6):
2330 - 2336.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. G. Horvath, S. M. Henshall, J. G. Kench, D. N. Saunders, C.-S. Lee, D. Golovsky, P. C. Brenner, G. F. O'Neill, R. Kooner, P. D. Stricker, et al.
Membranous Expression of Secreted Frizzled-Related Protein 4 Predicts for Good Prognosis in Localized Prostate Cancer and Inhibits PC3 Cellular Proliferation in Vitro
Clin. Cancer Res.,
January 15, 2004;
10(2):
615 - 625.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Augustin, M. Graefen, J. Palisaar, J. Blonski, A. Erbersdobler, F. Daghofer, H. Huland, and P. G. Hammerer
Prognostic Significance of Visible Lesions on Transrectal Ultrasound in Impalpable Prostate Cancers: Implications for Staging
J. Clin. Oncol.,
August 1, 2003;
21(15):
2860 - 2868.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Henshall, D. E. H. Afar, J. Hiller, L. G. Horvath, D. I. Quinn, K. K. Rasiah, K. Gish, D. Willhite, J. G. Kench, M. Gardiner-Garden, et al.
Survival Analysis of Genome-Wide Gene Expression Profiles of Prostate Cancers Identifies New Prognostic Targets of Disease Relapse
Cancer Res.,
July 15, 2003;
63(14):
4196 - 4203.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|